3-(4-methoxyphenyl)-5-methylisothiazole-4-carboxylic acid | 16188-20-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-methoxyphenyl)-5-methylisothiazole-4-carboxylic acid
• 英文别名: 3-(4-methoxy-phenyl)-5-methyl-isothiazole-4-carboxylic acid；3-(p-Methoxy-phenyl)-5-methyl-isothiazol-4-carbonsaeure；5-Methyl-3-(4-methoxyphenyl)isothiazol-4-carbonsaeure；3-(4-methoxyphenyl)-5-methyl-1,2-thiazole-4-carboxylic acid
• CAS: 16188-20-8
• 化学式: C₁₂H₁₁NO₃S
• 分子量: 249.29
• InChiKey: MXOCEHCHOINQER-UHFFFAOYSA-N

物化性质

• 熔点：
  148-150 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• 沸点：
  311.0±34.0 °C(Predicted)
• 密度：
  1.310±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(4-methoxyphenyl)-5-methylisothiazole-4-carboxylic acid 在 三溴化硼 、 sodium hydroxide 、 水 作用下， 以 二氯甲烷 为溶剂， 以96%的产率得到3-(4-hydroxyphenyl)-5-methylisothiazole-4-carboxylic acid
  参考文献：
  名称：

  Macrocyclic Acyl Guanidines as Beta-Secretase Inhibitors

  摘要：

  提供了一系列含杂环的大环酰基胍类化合物，其化学式为(I)或其立体异构体；或其无毒的药用可接受盐，其中R1、R2、R3、R4、R5、n和X如本文所定义，以及它们的药物组合物和使用方法。这些新化合物抑制β-分泌酶对淀粉样前体蛋白(APP)的加工，更具体地，抑制Aβ-肽的产生。本公开涉及用于治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物，例如阿尔茨海默病和其他受抗淀粉样活性影响的疾病。

  公开号：

  US20080262055A1
• 作为产物：
  描述：

  β-imino-β-(p-anisyl)propionitrile 在 氢氧化钾 、 硫化氢 作用下， 以 二氯甲烷 为溶剂， 生成 3-(4-methoxyphenyl)-5-methylisothiazole-4-carboxylic acid
  参考文献：
  名称：

  Naito,T. et al., Chemical and pharmaceutical bulletin, 1968, vol. 16, # 1, p. 148 - 159

  摘要：

  DOI：

文献信息

• Aminoacetamide acyl guanidines as beta-secretase inhibitors
  申请人：Gerritz Samuel

  公开号：US20060287287A1

  公开（公告）日：2006-12-21

  There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 2 , R 3 , R 4 , R 5 , R 25 , R 26 and R 27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列的取代酰基胍类化合物，符合以下化学式（Ik）或其立体异构体；或其药学上可接受的盐，其中R2、R3、R4、R5、R25、R26和R27如本文所定义，它们的药物组合物和使用方法。这些化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地说，抑制Aβ肽的产生。本公开涉及对β-淀粉样蛋白产生相关的神经疾病的治疗有用的化合物，如阿尔茨海默氏病和其他受抗淀粉样活性影响的病症。
• Acyl guanidines as beta-secretase inhibitors
  申请人：Gerritz Samuel

  公开号：US20070015754A1

  公开（公告）日：2007-01-18

  There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列的取代酰基鸟氨酸化合物（I）或其立体异构体；或其药学上可接受的盐，其中R1、R2、R3、R4和R5如本文所定义，以及它们的药物组合物和使用方法。这些化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地抑制Aβ-肽的产生。本公开涉及用于治疗与β-淀粉样蛋白产生有关的神经系统疾病，例如阿尔茨海默病和其他受抗淀粉样蛋白活性影响的疾病的化合物。
• Macrocyclic acyl guanidines as beta-secretase inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US07732434B2

  公开（公告）日：2010-06-08

  There is provided a series of heterocyclic-containing macrocyclic acyl guanidines of Formula (I) or a stereoisomer; or a nontoxic pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列含杂环的大环酰基胍化合物，其化学式为（I）或其立体异构体；或其无毒的药学上可接受的盐。其中，R1、R2、R3、R4、R5、n和X的定义如本文所述，以及它们的制药组合物和使用方法。这些新化合物抑制β-分泌酶对淀粉样前体蛋白(APP)的加工，更具体地抑制Aβ-肽的产生。本公开涉及的化合物可用于治疗与β-淀粉样蛋白产生有关的神经系统疾病，如阿尔茨海默病和其他受抗淀粉样蛋白活性影响的疾病。
• NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS
  申请人：Cianci Christopher W.

  公开号：US20120245176A1

  公开（公告）日：2012-09-27

  A compound of Formula I is set forth, including pharmaceutically acceptable salts thereof: wherein Het is a 5 or 6-membered heterocycle with —N, —O, or —S adjacent to the —Ar substituent or adjacent to the point of attachment for the —Ar substituent; Ar is aryl or heteroaryl; R is —CH 3 , —CH 2 F, —CHF 2 or —CH═CH 2 ; V is —H, —CH 3 or ═O; W is —NO 2 , —Cl, —Br, —CH 2 OH, or —CN; X is —Cl, —Br, —F, —CH 3 , —OCH 3 , or —CN; Y is —CH or —N; and Z is —CH or —N. This compound is useful in compositions for the prevention and treatment of influenza virus.

  本发明涉及一种I式化合物，包括其药学上可接受的盐：其中，Het是一种5或6元杂环，其中- N，-O或-S与-Ar取代基相邻或与-Ar取代基的连接点相邻；Ar是芳基或杂芳基；R是-CH3，-CH2F，-CHF2或-CH═CH2；V是-H，-CH3或═O；W是-NO2，-Cl，-Br，-CH2OH或-CN；X是-Cl，-Br，-F，-CH3，-OCH3或-CN；Y是-CH或-N；以及Z是-CH或-N。该化合物在预防和治疗流感病毒的组合物中有用。
• Acyl Guanidine Inhibitors of β-Secretase (BACE-1): Optimization of a Micromolar Hit to a Nanomolar Lead via Iterative Solid- and Solution-Phase Library Synthesis
  作者：Samuel W. Gerritz、Weixu Zhai、Shuhao Shi、Shirong Zhu、Jeremy H. Toyn、Jere E. Meredith、Lawrence G. Iben、Catherine R. Burton、Charles F. Albright、Andrew C. Good、Andrew J. Tebben、Jodi K. Muckelbauer、Daniel M. Camac、William Metzler、Lynda S. Cook、Ramesh Padmanabha、Kimberley A. Lentz、Michael J. Sofia、Michael A. Poss、John E. Macor、Lorin A. Thompson

  DOI：10.1021/jm300931y

  日期：2012.11.8

  This report describes the discovery and optimizition of a BACE-1 inhibitor series containing an unusual acyl guanidine chemotype that was originally synthesized as part of a 6041-membered solid-phase library. The synthesis of multiple follow-up solid- and solution-phase libraries facilitated the optimization of the original micromolar hit into a single-digit nanomolar BACE-1 inhibitor in both radioligand binding and cell-based functional assay formats. The X-ray structure of representative inhibitors bound to BACE-1 revealed a number of key ligand:protein interactions, including a hydrogen bond between the side chain amide of flap residue Gln73 and the acyl guanidine carbonyl group, and a cation-pi interaction between Arg235 and the isothiazole 4-methoxyphenyl substituent. Following subcutaneous administration in rats, an acyl guanidine inhibitor with single-digit nanomolar activity in cells afforded good plasma exposures and a dose-dependent reduction in plasma A beta levels, but poor brain exposure was observed (likely due to Pgp-mediated efflux), and significant reductions in brain A beta levels were not obtained.